Ngm Biopharmaceuticals Stock Price, News & Analysis

NGM has entered a clinical trial collaboration with Merck to evaluate NGM707 in combination with KEYTRUDA for treating advanced solid tumors. This trial aims to assess the dual antagonist's potential to enhance immune response against tumors expressing ILT2 and ILT4. Currently, the Phase 1/2 trial is enrolling patients, focusing on how NGM707 might reverse immune suppression in tumors. Initial preclinical studies suggest that combining NGM707 with KEYTRUDA could amplify T-cell activation and cytokine secretion, offering hope for improved cancer therapies.

NGM Biopharmaceuticals, Inc. (NGM) announced CEO David J. Woodhouse, Ph.D. will present at several upcoming virtual investor conferences. The Stifel 2021 Virtual Healthcare Conference will take place on November 15, 2021, at 2:40 p.m. ET. The Jefferies London Healthcare Conference is scheduled for November 18-19, with an on-demand presentation starting November 18 at 3:00 a.m. ET. The Piper Sandler Healthcare Conference occurs from November 30 to December 2, 2021, with an on-demand presentation available November 22, and the Evercore ISI Healthcare Conference on December 1 at 1:25 p.m. ET.

NGM Biopharmaceuticals reported promising progress in its oncology portfolio during Q3 2021, showcasing preliminary data from NGM120 trials at ESMO 2021. Notably, all evaluable metastatic pancreatic cancer patients showed disease control at 16 weeks. The company initiated clinical studies for NGM707 and disclosed NGM831 as part of its pipeline. Financially, NGM reported a net loss of $28.9 million, a slight decrease from $29.8 million a year ago. Cash reserves improved to $383.4 million, compared to $295.2 million at the end of 2020, highlighting a strong liquidity position.

NGM Biopharmaceuticals announced preliminary findings from its Phase 1a/1b study of NGM120, a GFRAL antagonist antibody aimed at treating advanced solid tumors, particularly metastatic pancreatic cancer. The study demonstrated that NGM120 was well tolerated without dose-limiting toxicities. In the Phase 1b cohort, all six evaluable patients showed disease control at 16 weeks, with three partial responses and three stable disease outcomes. Four patients continued to exhibit responses beyond 36 weeks. NGM plans to report final results post-completion of treatment.

NGM Biopharmaceuticals announced the discovery of ILT3's functional ligand, fibronectin, which could form a stromal checkpoint suppressing myeloid cell function and inhibiting antitumor immunity. Their new candidate, NGM831, is designed to block ILT3's interactions with fibronectin and other ligands. First-in-human testing of NGM831 is planned for the first half of 2022.

NGM's oncology portfolio now includes four candidates targeting ILT2/ILT4, ILT3, and LAIR1, aimed at enhancing antitumor immunity.

NGM Biopharmaceuticals (NGM) has completed enrollment in the 320-patient Phase 2 CATALINA study of NGM621 for geographic atrophy, with topline data expected in late 2022. The company initiated a Phase 1/2 trial of NGM707 for solid tumors and amended its collaboration with Merck to focus on retinal and cardiovascular diseases. NGM reported a net loss of $36.7 million for Q2 2021, a rise from $25.6 million in 2020, with an increase in R&D expenses to $43.6 million. NGM's cash and equivalents stood at $390.6 million as of June 30, 2021, up from $295.2 million at year-end 2020.

NGM Biopharmaceuticals has completed enrollment in the Phase 2 CATALINA study evaluating NGM621 for treating geographic atrophy associated with age-related macular degeneration. This monoclonal antibody targets complement C3 to slow disease progression, with enrollment exceeding the initial estimate of 240 patients, now totaling 320. The trial will assess the efficacy and safety of NGM621, with topline data expected in the second half of 2022. Geographic atrophy currently has no approved treatments, impacting about 1 million patients in the U.S. and 5 million globally.

NGM Biopharmaceuticals, Inc. (NGM) has initiated a Phase 1/2 study for NGM707, a dual antagonistic antibody targeting ILT2 and ILT4, designed to enhance anti-tumor immune responses. The study will evaluate NGM707 as a monotherapy and combined with KEYTRUDA® (pembrolizumab) in approximately 180 patients with elevated ILT2 and ILT4 expressions across various advanced solid tumors. Preliminary efficacy signals will also be assessed, focusing on safety and tolerability. This marks NGM's second oncology candidate in clinical trials, following NGM120.

NGM Biopharmaceuticals and Merck have amended their collaboration to focus on retinal and cardiovascular diseases through March 2024. Merck will continue funding NGM with approximately $120 million for research and development. NGM retains rights to its oncology portfolio and other undisclosed assets, allowing for greater independence in advancing its programs. This collaboration revision supports ongoing clinical trials for NGM621 and MK-3655 while allowing NGM to explore new opportunities in therapeutics. Merck’s option to license NGM’s developed assets remains intact.